Physician profile
Robert C Davidson
NPI 1003809641
$4,682.80
in general payments reported to CMS, 2019-2025
22 companies · $820 in 2025
The $820 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,049 · 2020: $546 · 2021: $282 · 2022: $763 · 2023: $442 · 2024: $781 · 2025: $820.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,042.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,042.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $612.10 | 2019-2021 | |
| Alcon Vision LLC | $511.48 | 2019-2025 | Clareon, Unity, Clareon Panoptix Pro |
| Glaukos Corporation | $500.92 | 2024-2025 | Idosetr, Idose |
| Bausch & Lomb Americas INC. | $447.17 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Johnson & Johnson Surgical Vision, INC. | $445.24 | 2019-2025 | Tecnis Simplicity, Tecnis Iol |
| Abbvie INC. | $432.29 | 2022-2025 | Durysta |
| Allergan, INC. | $390.49 | 2019-2022 | |
| Rxsight INC | $192.62 | 2023-2024 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Contact Lens |
| Aerie Pharmaceuticals, INC. | $186.87 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $182.33 | 2019-2021 | |
| Omeros Corporation | $134.30 | 2019 | |
| Carl Zeiss Meditec USA, INC. | $122.92 | 2022-2025 | |
| Sight Sciences, INC. | $116.06 | 2020 | |
| Genentech USA, INC. | $81.04 | 2022 | |
| Tarsus Pharmaceuticals, INC. | $60.16 | 2024-2025 | Xdemvy |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kala Pharmaceuticals, INC. | $57.97 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $53.87 | 2022 | |
| Sun Pharmaceutical Industries INC. | $42.11 | 2019 | |
| Shire North American Group INC | $41.69 | 2019 | |
| Oyster Point Pharma, INC. | $33.45 | 2022-2023 | Tyrvaya |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Ocular Therapeutix, INC. | $18.32 | 2023 | Dextenza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Davidson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.